Someone tests at 24 in one laboratory and 31 in another, three weeks apart, having changed nothing about their supplement. One result is labelled insufficient and the other is labelled adequate, and the difference is entirely an artefact of how the two laboratories measure the same molecule. This is not a rare mishap. Vitamin D has historically been one of the least comparable measurements in routine clinical chemistry, and although the situation has improved substantially, it has not been fully solved.
The reasons are worth understanding, because they are not really about vitamin D. They are about what happens when a small, greasy molecule that travels bound to a carrier protein has to be extracted, recognised and quantified by instruments that each solve those problems differently. Add to that a biological quantity that swings with the seasons and a definition of deficiency that experts genuinely disagree about, and you have a test where the number needs more interpretation than most.
None of this makes the test useless. It makes the test something to read with a wide margin rather than a sharp threshold.
Key takeaways
- Laboratories measure 25-hydroxyvitamin D, a storage form, not the active hormone the body actually uses.
- Immunoassay and mass spectrometry platforms can return different values on the same sample, particularly at low concentrations.
- Supplementation with vitamin D2 rather than D3 creates a specific measurement problem some assays handle poorly.
- The threshold separating sufficiency from insufficiency is a matter of active expert disagreement, not settled fact.
- Season, latitude and skin tone shift results predictably enough that the collection date matters when comparing two tests.
Which Vitamin D Metabolite Labs Actually Measure
Vitamin D is not one substance but a small family of related compounds at different stages of processing. Skin exposed to ultraviolet B light produces cholecalciferol, vitamin D3. Diet and supplements supply either D3 or ergocalciferol, D2, which comes from fungal and plant sources. Neither is biologically active as it stands.
The liver adds a hydroxyl group to produce 25-hydroxyvitamin D, and this is the compound laboratories measure. It has a circulating half-life measured in weeks, which makes it a stable reflection of accumulated supply rather than a snapshot of yesterday. It also circulates at concentrations high enough to be measured reliably, which matters for a molecule present in vanishingly small amounts.
The kidney then adds a second hydroxyl group to make 1,25-dihydroxyvitamin D, the hormone that actually binds the vitamin D receptor and drives calcium absorption. It would seem more logical to measure that one, and occasionally it is measured, but for assessing nutritional status it is close to misleading. Its concentration is tightly regulated by parathyroid hormone, and in early deficiency the body compensates by making more of it. A person genuinely short of vitamin D can therefore show a perfectly normal or even raised active hormone level while their stores run down. The active form is ordered for specific problems involving calcium regulation, not for asking whether someone needs more vitamin D.
Almost all of the circulating 25-hydroxyvitamin D is bound to vitamin D binding protein, with a small further fraction on albumin and only a sliver genuinely free. That binding is the first practical obstacle any assay has to overcome, because a bound molecule is hidden from the antibody or the detector until it is released.
Immunoassay Versus Mass Spectrometry Results
Two broad approaches dominate. Automated immunoassays use an antibody that recognises 25-hydroxyvitamin D, run on the same high-throughput analysers that handle thyroid hormones and cardiac markers. They are fast, cheap and require no specialist operator, which is why the great majority of routine vitamin D results come from them.
Liquid chromatography tandem mass spectrometry takes the harder road. The sample is treated to strip the vitamin off its binding protein, the extract is separated on a chromatographic column so that different molecules emerge at different times, and each is then identified by its mass and by the characteristic fragments it breaks into. Rather than asking an antibody whether something looks like vitamin D, the instrument measures physical properties that are close to unforgeable.
| Feature | Automated immunoassay | LC-MS/MS |
|---|---|---|
| What identifies the molecule | Antibody binding shape | Mass and fragmentation pattern |
| Separates D2 from D3 | Usually not | Yes, reported separately |
| Release from binding protein | Chemical displacement in the reagent | Physical extraction step |
| Typical turnaround | Same day, high volume | Batched, slower |
| Main weakness | Cross-reactivity and matrix effects | Cost, operator skill, ion suppression |
The critical difference is that the immunoassay reports a single number that represents whatever its antibody happened to bind. If the antibody also binds a related metabolite, that contribution is silently included. Mass spectrometry can see the components separately and report them separately, which is why it is treated as the reference approach when accuracy matters more than throughput.
The D2 and D3 Cross-Reactivity Problem
Vitamin D2 and D3 differ by a single side-chain feature. To an antibody raised against one of them, that difference may be barely visible or it may be decisive, and this varies from assay to assay in ways that are not obvious from the result slip.
The consequence appears in people taking high-dose prescription vitamin D2, which is still used in some regions. Their circulating pool contains substantial 25-hydroxyvitamin D2 alongside whatever D3 they have from sun and diet. An immunoassay that under-recognises the D2 form will report a total that is too low, sometimes strikingly so, and a clinician may respond by increasing a dose that was already working. An assay that over-recognises it errs the other way. Mass spectrometry sidesteps the problem entirely by reporting both metabolites and summing them explicitly.
A second cross-reactivity issue involves a metabolite called 24,25-dihydroxyvitamin D, which accumulates when the body is clearing excess vitamin D. Some antibodies pick it up, inflating results in exactly the people least likely to need more. There is also an epimer, a mirror-image variant that is common in infants and present at lower levels in adults, which most immunoassays cannot distinguish and which some chromatographic methods will separate only if the column and conditions are chosen deliberately.
None of these interferences produce wild errors in most people most of the time. They produce a modest, direction-dependent bias that is invisible unless you know the platform, and they are one reason a single result should not be treated as a precise value.
Why Cut-Offs for Deficiency Are Contested
Even with a perfect measurement, there would still be an argument about what the number means, because different expert bodies have used different reasoning to set their thresholds.
One approach asks what concentration is needed to prevent frank bone disease, rickets in children and osteomalacia in adults. That question has a reasonably clear answer, and it produces a low threshold. A second approach asks what concentration suppresses parathyroid hormone and maximises calcium absorption, which produces a somewhat higher threshold because those physiological endpoints keep improving above the level where bone disease disappears. A third approach asks what concentration is associated with the broadest range of favourable health outcomes in observational data, which produces higher numbers still and rests on the weakest evidence, since observational associations with vitamin D are notoriously confounded by outdoor activity, body composition and general health.
The result is that major bodies have published thresholds that differ, and that a laboratory’s choice of which to print on the report determines whether a given patient is told they are deficient. The word “insufficient” carries particular weight here: it describes a middle zone that some organisations recognise and others do not, and it has driven an enormous amount of supplementation in people whose bones were never at risk.
Reading a vitamin D result therefore means reading the laboratory’s stated ranges as one interpretation among several. A value near a threshold has not crossed a biological boundary. It has crossed a line drawn by a committee.
Seasonal and Latitude Effects on Results
Skin synthesis depends on ultraviolet B reaching the dermis, and the amount of UVB that penetrates the atmosphere depends on the angle of the sun. Above roughly the latitudes of northern Europe and the northern United States, that angle is too shallow through the winter months for meaningful synthesis to occur at all, whatever the weather feels like. People in those regions draw down stores through winter and rebuild them through summer.
The practical effect is a predictable annual cycle, with the trough falling in late winter or early spring and the peak in late summer. The swing is large enough that the same person can move between two different interpretive categories without any change in behaviour. Comparing a March result with the previous August result and concluding that something has gone wrong is a common error.
Other factors shift the baseline in reasonably consistent directions. More melanin in the skin absorbs UVB and lengthens the exposure needed for the same synthesis, which is one contributor to the lower average measurements seen in darker-skinned populations at high latitudes. Older skin synthesises less efficiently. Vitamin D is fat-soluble and distributes into adipose tissue, so a larger fat mass tends to dilute the circulating concentration for a given intake. Consistent sunscreen use and covering clothing reduce synthesis, as does spending the daylight hours indoors.
For interpretation, this means the collection month belongs beside the number. A late-summer result at the bottom of the range is a more concerning finding than the identical value taken in February.
Standardisation Programmes and Assay Alignment
The scale of the between-laboratory disagreement became undeniable when external quality assessment schemes began circulating identical samples to many laboratories and publishing the spread of returned values. The spread was wide, and it was systematic rather than random: particular platforms read consistently high or consistently low against each other.
The response was to build a reference measurement system. A definitive reference method based on isotope-dilution mass spectrometry was established, reference materials with certified values were produced by national metrology institutes, and manufacturers were invited to recalibrate their assays so that they traced back to that common anchor. National standardisation programmes then offered laboratories a way to check and demonstrate their alignment.
This has worked, in the sense that the between-method spread has narrowed considerably and that a modern result from a participating laboratory is far more comparable to another than it would have been before. It has not worked completely. Standardising the calibration fixes systematic offset; it does not fix cross-reactivity, which is a property of the antibody, nor does it fix matrix effects that differ between an idealised reference material and real human serum from an unwell patient.
There is also a practical gap: not every laboratory participates, and the report rarely says whether this one does. A laboratory that states its method and mentions standardisation on the report is telling you something useful, and it is reasonable to ask.
Deciding Whether Retesting Is Worthwhile
Given all of the above, the most useful discipline is to decide in advance what a repeat test would change. If the answer is nothing, the test is not worth doing.
Where retesting genuinely earns its place is in confirming that treatment of a clearly low result has worked, in people with conditions that impair absorption or alter vitamin D metabolism, in those on high doses where the question is safety rather than sufficiency, and in anyone with unexplained bone pain, fractures or abnormal calcium. In those situations a follow-up measurement answers a real question.
Where it usually adds nothing is in the well person with a mid-range result who wants to watch the number move. Between the analytical variation of the assay, the biological variation of the individual and the seasonal cycle, small differences between two results carry almost no information. Chasing them tends to produce dose adjustments in response to noise.
If a repeat is worth doing, three things make it more informative: use the same laboratory and the same method, allow enough time for the long half-life to settle after any dose change, and note the season. Comparing like with like turns a pair of numbers into a trend. Comparing a mass spectrometry result from one provider with an immunoassay result from another, taken in different months, produces a difference that is real on paper and meaningless in the body.
Frequently asked questions
Does a low vitamin D result mean I definitely need a supplement?
Not automatically, because the decision depends on how low, which threshold your laboratory used, and what else is going on. A value well below the level associated with bone disease is a clear finding that warrants action. A value sitting in the contested middle zone, taken at the end of winter in a person with no symptoms and normal calcium, is a much weaker signal, and different clinicians will reasonably reach different conclusions about it. The number is one input rather than an instruction.
Should I ask for the mass spectrometry version of the test?
For most people it is not necessary, because a standardised immunoassay from an accredited laboratory answers the ordinary question adequately. It becomes worth asking about in specific situations: when someone is taking vitamin D2 rather than D3, when results are wildly inconsistent between tests, when the result conflicts with the clinical picture, or in infants where the epimer is present at higher levels. In those cases the ability to separate and report the individual metabolites is what you are paying for.
Why did my result drop when I did not change anything?
Season is the first thing to check, since the natural annual cycle can move a person a substantial distance without any change in supplement or diet. Changing laboratories or platforms is the second, because a different method can carry a different bias. Weight change matters too, as vitamin D redistributes into fat tissue. Finally, ordinary analytical imprecision means two samples from the same person on the same day would not return identical numbers, so small differences between tests months apart should not be over-read.
Is a very high vitamin D result dangerous?
The risk from vitamin D itself is not the measured concentration but the calcium disturbance that can follow prolonged high intake, which is why anyone with a markedly raised level should have calcium checked rather than simply stopping the supplement and forgetting about it. Genuine toxicity is uncommon and generally requires sustained large doses rather than ordinary supplementation. It is also worth remembering that some assays over-recognise clearance metabolites, so a surprisingly high value in someone on a modest dose deserves confirmation before it is acted on.
Does testing before starting a supplement actually help?
It helps when the result would change what you do. If a clinician would recommend the same modest dose regardless of the number, the test is decorative. If the plan depends on the answer, for example deciding between routine maintenance and a corrective course, or if there is a reason to suspect a malabsorption or metabolic problem, then a baseline is worth having, not least because it gives a comparison point measured on the same platform for any future test.
This is education, not medical advice. Laboratory results only carry meaning alongside your symptoms, history and examination. Talk to a qualified clinician about your own results before changing anything about your care or supplements.
